FDA again rejects Atara, Pierre Fabre’s cell therapy for Epstein-Barr virusnews2026-01-12T13:59:22+00:00January 12th, 2026|Endpoints News|
Sanofi calls rejection of potential MS blockbuster ‘unexpected’news2026-01-08T20:40:39+00:00January 8th, 2026|Endpoints News|
FDA staff cuts mostly didn’t impact new drug review timelines, analysis findsnews2026-01-08T19:20:55+00:00January 8th, 2026|Endpoints News|
FDA rejects Vanda’s jet lag drug following yearslong dispute news2026-01-08T16:19:50+00:00January 8th, 2026|Endpoints News|
FDA drug and biologic approvals list 2025: Sign-offs dip during agency upheavalnews2026-01-08T16:00:45+00:00January 8th, 2026|Endpoints News|
Deregulating the rapidly evolving digital health industrynews2026-01-08T15:34:52+00:00January 8th, 2026|Endpoints News|
FDA in 2025 holds fewest number of adcomms since the pandemicnews2026-01-07T18:28:09+00:00January 7th, 2026|Endpoints News|
Post-Hoc Live Jan. 8: Fewer drugs, more chaos — a year under the new FDAnews2026-01-07T17:00:22+00:00January 7th, 2026|Endpoints News|
FDA Approves New 2-Gram Presentation of Fibryga®, Enhancing Convenience and Precision in Treating Acquired Fibrinogen DeficiencyFDA Approves New 2-Gram Presentation of Fibryga®, Enhancing Convenience and Precision in Treating Acquired Fibrinogen Deficiencynews2026-01-07T16:53:24+00:00January 7th, 2026|Medical Device News Magazine|
Drugmakers frustrated by vaccine schedule overhaulnews2026-01-06T21:15:01+00:00January 6th, 2026|Endpoints News|
